Drug General Information (ID: DDIO0XE7TM)
Drug Name			Peginterferon alfa-2a		Drug Info		Sargramostim		Drug Info
Drug Type		Interferons				Protein/peptide
Therapeutic Class		Antineoplastics				Colony Stimulating Factors

Mechanism of Peginterferon alfa-2a-Sargramostim Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Peginterferon alfa-2a				Sargramostim
Mechanism		Reduce therapeutic efficacy of hematopoietic growth factors				Hematopoietic growth factors
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Peginterferon alfa-2a when combined with Sargramostim

Recommended Action
Management		Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.

References
1	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
2	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
3	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.